Literature DB >> 385500

Experimental gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone.

S E Greisman, J B DuBuy, C L Woodward.   

Abstract

Outbred Swiss mice were inoculated intraperitoneally or intravenously with one 90 to 100% lethal dose of Escherichia coli O:18, Proteus mirabilis, or Klebsiella pneumoniae. After carefully timed intervals, aminoglycoside antibiotics were begun at dosages nnd intervals predetermined to constitute optimal therapy. With progressive increases in delay of antibiotic therapy, mortality rates increased progressively from 0% to 90 to 100%. Standardized models of infection were developed by selecting delay periods before initiating antibiotic therapy such that 50 to 70% mortalities resulted. Utilizing these models, agents with reputed anti-endotoxin activity were administered concomitantly with the delayed antibiotic therapy to determine if any could prevent gram-negative septic mortality no longer preventable by the antibiotics alone. The following were observed: (i) adrenal corticosteroids prevented mortality that was no longer preventable by optimal aminoglycoside antibiotics alone. The following were preventable by optimal aminoglycoside antibiotic therapy alone; (ii) specific antisera also did so, provided anaphylaxis was circumvented; (iii) in one model (P. mirabilis), such protection by adrenal corticosteroids and specific antiserum could be additive; (iv) adrenal corticosteroids and specific antiserum acted synergistically with the aminoglycoside antibiotics--no protection was achieved by delayed administration of the steroids or antiserum alone; (v) timing was crucial--the synergistic protective activity of adrenal corticosteroids and of specific antiserum with aminoglycosides declined rapidly as infection progressed; (vi) cyclophosphamide pretreatment markedly impaired the synergistic protective activity of specific antiserum and of adrenal corticosteroids with aminoglycosides; (vii) no reputed anti-endotoxin agents other than adrenal corticosteroids and specific antiserum proved capable of preventing mortality not preventable by aminoglycoside antibiotics alone. These included antisera to rough mutant Enterobacteriaceae of Rc, Rd, and Re chemotypes, anticoagulants (heparin), ascorbic acid, antiproteolytic agents (aprotinin), alpha adrenergic blockers (phenoxybenzamine), prostaglandin synthetase inhibitors (acetylsalicylic acid, sodium salicylate, indomethacin), nicotinamide, glucose, and insulin-glucose-potassium mixtures.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 385500      PMCID: PMC443579          DOI: 10.1128/iai.25.2.538-557.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Influence of oral glucose feeding on endotoxin lethality in mice.

Authors:  G Lazar; M K Agarwal
Journal:  Experientia       Date:  1977-10-15

2.  Experimental gram-negative bacterial sepsis: reevaluation of the ability of rough mutant antisera to protect mice.

Authors:  S E Greisman; J B DuBuy; C L Woodward
Journal:  Proc Soc Exp Biol Med       Date:  1978-07

3.  Effect of glucose-insulin-postassium on survival in experimental endotoxic shock.

Authors:  J Manny; N Rabinovici; N Manny; M Schiller; H B Hechtman
Journal:  Surg Gynecol Obstet       Date:  1978-09

4.  Relationship of structure to function in bacterial endotoxins: serologically cross-reactive components and their effect on protection of mice against some gram-negative infections.

Authors:  A K Ng; C L Chen; C M Chang; A Nowotny
Journal:  J Gen Microbiol       Date:  1976-05

5.  Effects of glucose or insulin on myocardial performance in endotoxin shock.

Authors:  L B Hinshaw; L T Archer; B Benjamin; C Bridges
Journal:  Proc Soc Exp Biol Med       Date:  1976-09

6.  Passive immunity against pseudomonas sepsis during granulocytopenia.

Authors:  L Harvath; B R Andersen; H J Amirault
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

7.  Reversal of myocardial dysfunction in endotoxin shock with insulin.

Authors:  L T Archer; B K Beller; J K Drake; T L Whitsett; L B Hinshaw
Journal:  Can J Physiol Pharmacol       Date:  1978-02       Impact factor: 2.273

8.  Steroids in the treatment of clinical septic shock.

Authors:  W Schumer
Journal:  Ann Surg       Date:  1976-09       Impact factor: 12.969

9.  Experimental pneumonia due to Pseudomonas aeruginosa in leukopenic dogs: prolongation of survival by combined treatment with passive antibody to Pseudomonas and granulocyte transfusions.

Authors:  J A Kazmierowski; H Y Reynolds; J C Kauffman; W A Durbin; R G Graw; H B Devlin
Journal:  J Infect Dis       Date:  1977-03       Impact factor: 5.226

10.  Glucocorticoid and antibiotic effects on hepatic microcirculation and associated host responses in lethal gram-negative bacteremia.

Authors:  J U Balis; J F Paterson; S A Shelley; C H Larson; J Fareed; L I Gerber
Journal:  Lab Invest       Date:  1979-01       Impact factor: 5.662

View more
  19 in total

1.  Early antimicrobial therapy in severe sepsis and septic shock.

Authors:  Anand Kumar
Journal:  Curr Infect Dis Rep       Date:  2010-09       Impact factor: 3.725

Review 2.  New insights into the epidemiology, pathogenesis and therapy of Pseudomonas aeruginosa infections.

Authors:  S J Cryz
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

Review 3.  Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity.

Authors:  Isaac J Jensen; Frances V Sjaastad; Thomas S Griffith; Vladimir P Badovinac
Journal:  J Immunol       Date:  2018-03-01       Impact factor: 5.422

Review 4.  New frontiers in thermoregulation and exercise.

Authors:  P L Moseley; C V Gisolfi
Journal:  Sports Med       Date:  1993-09       Impact factor: 11.136

5.  The importance of anti-lipid A (anti-endotoxin): prevention of "shock lung" and acute renal failure.

Authors:  E N Wardle
Journal:  World J Surg       Date:  1982-09       Impact factor: 3.352

6.  Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis.

Authors:  Yan Li; Xizhong Cui; Xuemei Li; Steven B Solomon; Robert L Danner; Steven M Banks; Yvonne Fitz; Djillali Annane; Charles Natanson; Peter Q Eichacker
Journal:  Intensive Care Med       Date:  2007-11-09       Impact factor: 17.440

7.  Nosocomial bacteremia in a medical-surgical intensive care unit: epidemiologic characteristics and factors influencing mortality in 111 episodes.

Authors:  J Rello; M Ricart; B Mirelis; E Quintana; M Gurgui; A Net; G Prats
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

8.  Pneumonia-induced sepsis in mice: temporal study of inflammatory and cardiovascular parameters.

Authors:  Regina Sordi; Octávio Menezes-de-Lima; Ana M Della-Justina; Edir Rezende; Jamil Assreuy
Journal:  Int J Exp Pathol       Date:  2013-02-27       Impact factor: 1.925

9.  Non-specific influence of antibiotics on the course of infectious processes.

Authors:  G Gillissen
Journal:  Infection       Date:  1982       Impact factor: 3.553

10.  Methylprednisolone prevention of increased lung vascular permeability following endotoxemia in sheep.

Authors:  K L Brigham; R E Bowers; C R McKeen
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.